Dublin, Dec. 26, 2024 (GLOBE NEWSWIRE) -- The "Viral Vaccines Market Size, Share, Forecast, & Trends Analysis by Form Type, Route of Administration, Approach, Indication, Packaging - Global Forecast to 2031" report has been added to ResearchAndMarkets.com's offering.
According to the report, the viral vaccines market is projected to reach $64.18 billion by 2031, at a CAGR of 9.3% from 2024 to 2031.
The growth of this market is driven by the increasing government focus on immunization programs, technological advances in vaccine administration, and the use of inactivated vaccines in surgeries and treatments. However, the high costs of vaccine development and the long timelines of vaccine manufacturing restrain the growth of this market.
Furthermore, the growing focus on therapeutic vaccines, this increasing use of adjuvants in vaccines, growth prospects in emerging markets, and the development of highly stable and energy-efficient ultra-low-temperature freezers are expected to generate growth opportunities for market stakeholders. However, product recalls and inadequate access to vaccines are major challenges impacting the market's growth.
The report includes an extensive assessment of the leading players' product portfolio and geographic presence and the key growth strategies adopted by them over the past three to four years. In recent years, the viral vaccines market has witnessed several organic and inorganic strategic developments.
The key players profiled in the viral vaccines market report are Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), AstraZeneca plc (U.K.), CSL Limited (Australia), Merck & Co., Inc. (U.S.), Sanofi (France), Sinovac Biotech Ltd. (China), Moderna, Inc. (U.S.), Valneva SE (France), Dynavax Technologies Corporation (U.S.), EMERGENT BIOSOLUTIONS INC. (U.S.), Johnson & Johnson (U.S.), Bharat Biotech Ltd. (India), and Serum Institute of India Pvt. Ltd. (India).
Increasing Use of Adjuvants in Vaccines
Conventional live-attenuated vaccines have proven effective for various indications, such as smallpox, measles, and polio, in most cases. However, these vaccines often come with side effects, including fever, rashes, and vaccine-derived infections. Additionally, large-scale production and issues related to vaccine consistency present significant challenges. To address these issues, adjuvant vaccines, which stimulate robust immune responses, were developed. Adjuvant vaccines contain only a small part of the pathogen, which helps reduce immunogenicity and minimizes side effects. Adjuvants in vaccines serve various purposes, including:
- Initiating the immune response to antigens by delivering them in their native form.
- Facilitating single-step vaccination, thereby reducing vaccination costs.
- Enhancing immune responses in immunocompromised individuals.
Until recently, aluminum-containing adjuvants were considered the gold standard for comparing other adjuvants. However, recent advancements have improved the physical, chemical, and biological properties of these adjuvants, reducing hypersensitivity reactions, carcinogenicity, teratogenicity, and toxicity in humans. Various modifications to adjuvant systems have also been made. For instance, oil-in-water emulsion-based adjuvants have been developed for human use due to their effective and promising results.
Additionally, virosome vaccines have been specifically designed for influenza treatment, offering effectiveness, quality, and long-lasting immune responses. Ongoing research is focused on selecting the best adjuvants - whether classical adjuvants, immunostimulants, or combinations - to enhance vaccine efficacy. As a result, advancements in adjuvant research and utilization present new growth opportunities for vaccine manufacturers.
Among the forms studied in this report, in 2024, the lyophilized vaccines segment is slated to register the highest CAGR of 11.1% of the viral vaccines market. Lyophilized viral vaccines are preserved through a freeze-drying process that removes excess water, enhancing their stability, extending shelf life, and making transportation easier. These vaccines are commonly used to prevent infections such as yellow fever, measles, mumps, rubella, and other viral diseases, offering advantages such as improved stability and transportability.
Among the vaccine types studied in this report, in 2024, the viral vector vaccines segment is slated to register the highest CAGR of 17% of the viral vaccines market. Viral vector vaccines use modified viruses to deliver genetic material into cells, prompting them to produce viral proteins that trigger an immune response. These vaccines offer several benefits, including a strong immune response, rapid development and scalability, broad effectiveness, and the potential for creating multivalent vaccines.
Among the approaches studied in this report, in 2024, the preventive vaccines segment is slated to register the highest CAGR of the viral vaccines market. This growth is driven by factors such as the increasing prevalence of chronic and infectious diseases, rising public awareness of immunization, and the expansion of immunization programs. For instance, in February 2024, the Union Minister for Finance & Corporate Affairs of India proposed a vaccination program under the Viksit Bharat by 2047 campaign aimed at preventing cervical cancer in girls aged 9 to 14.
Among the indications studied in this report, in 2024, the cancer segment is slated to register the highest CAGR of 24.1% of the viral vaccines market. Cancer prevalence is rising globally; according to GLOBOCAN, 20.0 million new cancer cases were reported in 2022, with this number projected to increase to 24.1 million by 2030. The growing prevalence of cancer highlights the need for preventive techniques to reduce human suffering and financial burdens. Vaccines play a crucial role in first-line prevention of premalignant conditions and cancer, as well as in secondary prevention for patients who have undergone curative treatments to reduce recurrence.
Among the routes of administration studied in this report, in 2024, the intramuscular segment is expected to account for the largest share of the viral vaccines market. The IM route, which involves administering vaccines into a patient's muscles, is preferred due to its ability to elicit a strong immune response, along with its safety, tolerability, and compatibility with various vaccine types.
Among the packaging types studied in this report, in 2024, the vials segment is slated to register the highest CAGR of the viral vaccines market. Vials, made from plastic or glass, are small containers used to package liquid or powdered medications. They provide a protective environment for viral vaccines, helping to maintain stability and efficacy by shielding the vaccines from external factors like moisture, light, and contamination.
Among the regions studied in this report, Asia-Pacific is slated to register the highest CAGR of 10.2% of the viral vaccines market. This growth is primarily attributed to the increasing prevalence of infectious diseases, growing public awareness of vaccines and immunization, government initiatives, high healthcare expenditure, and rising disposable incomes. For instance, in April 2024, Wockhardt Hospitals (India) launched an immunization program aimed at people of all age groups to emphasize the importance of vaccination.
Key Topics Covered
1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Factors Affecting Market Growth
4.2.1. Drivers
4.2.1.1. Increasing Government Focus on Immunization Programs
4.2.1.2. Technological Advancements in Vaccine Administration
4.2.2. Restraints
4.2.2.1. High Costs of Vaccine Development
4.2.2.2. Long Timelines of Vaccine Manufacturing
4.2.3. Opportunities
4.2.3.1. Growing Focus on Therapeutic Vaccines
4.2.3.2. Increasing Use of Adjuvants in Vaccines
4.2.3.3. Growth Prospects in Emerging Markets
4.2.4. Challenges
4.2.4.1. Product Recalls
4.2.4.2. Inadequate Access to Vaccines
4.2.5. Key Trends
4.2.5.1. Personalized Vaccines and Vaccinomics
4.2.5.2. Media and Public Awareness Regarding Immunization
4.3. Regulatory Analysis
4.4. Pricing Analysis
4.5. Porter's Five Forces Analysis
4.6. Pipeline Analysis
5. Viral Vaccines Market Assessment - by Form
5.1. Overview
5.2. Liquid Viral Vaccines
5.3. Lyophilized Viral Vaccines
6. Viral Vaccines Market - by Vaccine Type
6.1. Overview
6.2. mRNA Vaccines
6.3. Subunit & Conjugate Vaccines
6.4. Live-attenuated Vaccines
6.5. Inactivated Vaccines
6.6. Viral Vector Vaccines
6.7. Combination Vaccines
7. Viral Vaccines Market Assessment - by Route of Administration
7.1. Overview
7.2. Intramuscular (IM)
7.3. Subcutaneous (SC)
7.4. Oral
7.5. Other Routes of Administration
8. Viral Vaccines Market Assessment - by Approach
8.1. Overview
8.2. Preventive Vaccines
8.3. Therapeutic Vaccines
9. Viral Vaccines Market Assessment - by Indication
9.1. Overview
9.2. Influenza
9.3. Human Papillomavirus (HPV)
9.4. Rotavirus
9.5. Poliomyelitis (Polio)
9.6. Hepatitis
9.7. Cancer
9.8. Other Indications
10. Viral Vaccines Market Assessment - by Packaging
10.1. Overview
10.2. Vials
10.3. Prefilled Syringes
11. Coronavirus Disease
11.1. COVID-19: Overview
11.2. Coronavirus Prevalence
11.3. COVID-19 Market Assessment
12. Viral Vaccines Market Assessment - by Geography
12.1. Overview
12.2. North America
12.2.1. U.S.
12.2.2. Canada
12.3. Europe
12.3.1. Germany
12.3.2. U.K.
12.3.3. France
12.3.4. Italy
12.3.5. Spain
12.3.6. Switzerland
12.3.7. Ireland
12.3.8. Denmark
12.3.9. Belgium
12.3.10. Rest of Europe
12.4. Asia-Pacific
12.4.1. Japan
12.4.2. China
12.4.3. India
12.4.4. South Korea
12.4.5. Rest of Asia-Pacific
12.5. Latin America
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Middle East & Africa
13. Competitive Landscape
13.1. Introduction
13.2. Key Growth Strategies
13.3. Competitive Benchmarking
13.4. Competitive Dashboard
13.4.1. Industry Leaders
13.4.2. Market Differentiators
13.4.3. Vanguards
13.4.4. Emerging Companies
13.5. Market Share Analysis
14. Company Profiles
14.1. Pfizer Inc.
14.2. Glaxo Smith Kline plc
14.3. AstraZeneca plc
14.4. CSL Limited
14.5. Merck & Co. Inc.
14.6. Moderna, Inc.
14.7. Johnson & Johnson
14.8. Emergent Biosolutions Inc.
14.9. Bharat Biotech Ltd.
14.10. Sinovac Biotech Ltd.
14.11. Sanofi
14.12. Serum Institute of India Pvt. Ltd.
14.13. Dynavax Technologies Corporation
14.14. Valneva SE
For more information about this report visit https://www.researchandmarkets.com/r/31i9v4
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
